Want to track MGTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.53 per share a year ago.
Zacks | 1 year ago
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Bota-vec sale to JNJ/Janssen is complete – cash & future milestones from the deal should carry MeiraGTx through the next catalysts. The partnership with Sanofi strengthens the balance sheet and helps validate technology platforms. MGTX is no longer just an ocular GTx (gene therapy) company - its GTx for radiation-induced xerostomia has a high potential for success.
Seekingalpha | 1 year ago
